Transfusion-dependent adults with beta-thalassemia who received luspatercept were more likely to achieve clinically meaningful reductions in transfusion burden compared with placebo.
Downloadable slideset from a workshop series from Clinical Care Options (CCO) on the expanding treatment options for hemophilia A & B
From ASCO GI 2023, preliminary safety and efficacy data from the LEAP-015 study of pembrolizumab + lenvatinib + CT for gastroesophageal cancer, as reported by Clinical Care Options (CCO)
Data from ASCO GI 2023 from the SPOTLIGHT trial of zolbetuximab + mFOLFOX6 for CLDN18.2-positive/HER2-negative gastric cancers, as reported by Clinical Care Options (CCO)
On-demand webcast of a live symposium chaired by Dr Joyce O’Shaughnessy on biomarker-guided neo/adjuvant therapy for early breast cancer, from Clinical Care Options (CCO)